• Pioglitazone: A Translational PPARγ Strategy

  2026-08-17

  Pioglitazone is more than a metabolic research reagent: as a selective PPARγ agonist, it offers a controllable way to connect transcriptional regulation with insulin sensitivity, macrophage polarization, tissue-barrier integrity, and neuroinflammatory phenotypes. This article translates mechanistic evidence into practical design guidance for metabolic, inflammatory, and neurodegenerative research programs.

• Elobixibat Hydrate: From IBAT Biology to Translation

  2026-08-16

  Elobixibat hydrate offers a translationally distinctive way to connect intestinal bile acid handling with motility and metabolic endpoints. This thought-leadership article explains how to validate that mechanism, design fit-for-purpose experiments, interpret clinical signals, and move beyond the narrow perspective of a conventional product page.

• V5 Tagging as a Translational Control Layer

  2026-08-15

  A thought-leadership guide to using the V5 Epitope Tag Peptide as a reproducible control layer for protein detection, antibody validation, imaging, and translational assay development.

• Partial BACE Inhibition and Synaptic Transmission

  2026-08-14

  Satir et al. show that partial β-secretase inhibition can reduce amyloid β secretion by up to approximately 50% without impairing synaptic transmission in cultured primary cortical neurons. The study defines a potential exposure window for BACE inhibitor development while emphasizing that stronger inhibition may compromise neuronal function.

• Validated HPLC Analysis of Trelagliptin Succinate

  2026-08-14

  The reference study developed and validated a stability-indicating HPLC method that separates trelagliptin succinate from process-related and stress-generated impurities. By combining chromatographic validation with high-resolution tandem mass spectrometry, the work provides a practical quality-control framework for pharmaceutical dosage forms and related diabetes mellitus research workflows.

• Pioglitazone Workflows for PPARγ Research

  2026-08-13

  Build reproducible PPARγ activation assays across metabolic, macrophage, and neuroinflammation models with practical stock-preparation, dosing, and readout guidance. This workflow also translates recent STAT-1/STAT-6 macrophage findings into experiment-ready choices for inflammatory disease research.

• Berberine Hydrochloride: Applied Research Workflows

  2026-08-13

  Berberine hydrochloride connects AMPK-centered metabolic studies with practical LDLR, lipid, apoptosis, and oxidative-stress assays. This workflow-focused guide explains how to prepare the reagent, select model systems, translate cardiotoxicity findings responsibly, and troubleshoot the most common sources of variability.

• Quizartinib (AC220): From FLT3 Signal to Resistance

  2026-08-12

  Explore how Quizartinib (AC220) connects selective FLT3 inhibition with AML research, assay design, and resistance biology. This guide turns target engagement data into a more informative translational workflow.

• 2-Deoxy-D-glucose: Reproducible Assay Design

  2026-08-12

  Learn how 2-Deoxy-D-glucose (SKU B1027) can clarify glycolysis-dependent viability, proliferation, and cytotoxicity results through controlled dosing, formulation, and orthogonal readouts. This scenario-based guide separates product-supported parameters from workflow recommendations and highlights limitations when translating metabolic effects across cell models.

• Berberine hydrochloride: Reliable Cell Assays

  2026-08-11

  This scenario-driven guide shows how Berberine hydrochloride (SKU N1699) can improve experimental control in viability, proliferation, cytotoxicity, and mechanism-focused assays. It covers solubility, dosing, optical-readout controls, data interpretation, and practical vendor-selection criteria.

• CKI 7 dihydrochloride for Reliable Cell Assays

  2026-08-11

  This scenario-based guide explains how CKI 7 dihydrochloride, SKU B4936, can be incorporated into cell viability, proliferation, apoptosis, Wnt, circadian, and cancer biology workflows. It emphasizes mechanism-aware controls, solution handling, data interpretation, and practical reagent selection rather than treating pathway inhibition as a standalone cytotoxicity readout.

• Chlorpromazine Workflows for Neural and Liver Models

  2026-08-10

  Chlorpromazine hydrochloride supports controlled dopamine receptor signaling, antiemetic, and schizophrenia research while also serving as a pharmacological comparator in hepatic nanoparticle assays. This workflow connects receptor-focused experiments with cell-resolved nanoparticle uptake without overstating what either model can prove.

• GSK621: Reliable AMPK Assay Workflows

  2026-08-09

  Learn how GSK621 (SKU B6020) can strengthen AMPK-centered viability, proliferation, cytotoxicity, and immunometabolic assays. This scenario-based guide covers formulation, controls, readout interpretation, AML applications, and practical product-selection criteria.

• MK 0893: Glucagon Receptor Antagonist Guide

  2026-08-08

  MK 0893 is a competitive, reversible glucagon receptor antagonist that blocks GCGR signaling through an extra-helical allosteric site. It shows nanomolar inhibition of receptor binding and cAMP signaling and reduces glucagon-driven hyperglycemia in humanized mouse and primate models.

• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-08-07

  A 2025 Acta Diabetologica study identifies a direct vasorelaxant action of Anagliptin in phenylephrine-contracted rabbit aortic rings and links the response to voltage-dependent K+ channels and the SERCA pump. The findings extend evaluation of SK-0403 beyond glycemic pharmacology while defining important limits for interpretation in other vascular models.

14922 records 1/995 page Next 12345 下5页 Last page